ISCDD Recognizes Thomas Laughren, MD at ISCDD 11th Annual Meeting

BOCA RATON, Fla.--(BUSINESS WIRE)--The 11th Annual Meeting of the International Society for CNS Drug Development (ISCDD), brought together industry, academic, and government leaders involved in CNS drug development. The 2013 ISCDD Award was presented to Thomas Laughren, M.D., who recently retired from the position of director of the Division of Psychiatry Products in the Office of New Drugs in the Center for Drug Evaluation, FDA. Dr. Laughren has had a major impact on the lives of patients suffering with brain disorders in his roles in academia and government, where he is known for always focusing on patient needs and interests. He brought a level of academic expertise and openness to innovation in his regulatory role that has greatly advanced society's understanding of the true benefits and risks of psychiatric medications.